Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2015, Vol. 6 Issue (1) : 17-26     DOI: 10.14336/AD.2014.0514
|
Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration
Moura Alexandra1, Madureira José2, Alija Pablo2, Fernandes João Carlos3, Oliveira José Gerardo4, Lopez Martin5, Filgueiras Madalena6, Amado Leonilde7, Sameiro-Faria Maria7, Miranda Vasco7, Santos-Silva Alice8,9, Costa Elísio8,9,*
1Instituto de Ciências da Saúde, Universidade Católica Portuguesa, Porto, Portugal
2Clínica de Hemodiálise NefroServe, Barcelos, Portugal
3Clínica de Hemodiálise NefroServe, Viana do Castelo, Portugal
4Centro Hospitalar do Porto, Porto, Portugal
5Clínica de Hemodiálise de Felgueira, Felgueiras, Portugal
6Clínica de Hemodiálise de Gondomar, Gondomar, Portugal
7Clínica de Hemodiálise NephroCare, Maia, Portugal
8Laboratório de Bioquímica, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Portugal
9Instituto de Biologia Molecular e Celular, Universidade do Porto, Portugal.
Download: PDF(928 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

This work aimed to evaluate how aging could influence patients’ perception of health quality of life (HRQOL), as well as, the effect of aging on dialysis adequacy and in hematological, iron status, inflammatory and nutritional markers. In this transversal study were enrolled 305 ESRD patients under online-hemodiafiltration (OL-HDF) (59.67% males; 64.9 ± 14.3 years old). Data about comorbidities, hematological data, iron status, dialysis adequacy, nutritional and inflammatory markers were collected from patient’s records. Moreover, HRQOL score, by using the Kidney Disease Quality of Life-Short Form (KDQOL-SF), was assessed. Analyzing the results according to quartiles of age, significant differences were found for some parameters evaluated by the KDQOL-SF instrument, namely for work status, physical functioning and role-physical, which decreased with increasing age. We also found a higher proportion of diabetic patients, a decrease in creatinine, iron, albumin serum levels, transferrin saturation and nPCR, with increasing age. Moreover, significant negative correlations were found between age and mean cell hemoglobin concentration, iron, transferrin saturation, albumin, nPCR, work status, physical functioning and role-physical. In conclusion, our results showed that aging is associated with a decreased work status, physical functioning and role-physical, with a decreased dialysis adequacy, iron availability and nutritional status, and with an increased proportion of diabetic patients and of patients using central venous catheter, as the vascular access. The knowledge of these changes associated with aging, which have impact in the quality of life of the patients, could be useful in their management.

Keywords Health-related quality of life      on-line hemodiafiltration      aging      gender      dialysis adequacy      iron availability      nutritional status     
Corresponding Authors: Costa Elísio   
About author:

present address: Kunming Biomed International, Kunming, Yunnan, 650500, China

Issue Date: 01 February 2015
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Moura Alexandra
Madureira José
Alija Pablo
Fernandes João Carlos
Oliveira José Gerardo
Lopez Martin
Filgueiras Madalena
Amado Leonilde
Sameiro-Faria Maria
Miranda Vasco
Santos-Silva Alice
Costa Elísio
Cite this article:   
Moura Alexandra,Madureira José,Alija Pablo, et al. Effect of Aging in the Perception of Health-Related Quality of Life in End-Stage Renal Disease Patients under Online-Hemodiafiltration[J]. Aging and disease, 2015, 6(1): 17-26.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2014.0514     OR     http://www.aginganddisease.org/EN/Y2015/V6/I1/17
ESRD patients 1st quartile: < 56 years oldESRD patients 2nd quartile: 57–68 years oldESRD patients 3rd quartile:69–75 years oldESRD patients 4th quartile: > 75 years oldP value (ANOVA analysis) womenP value (ANOVA analysis) men
Women (n=25)Men (n=52)Women (n=32)Men (n=54)Women (n=31)Men (n=39)Women (n=35)Men (n=37)
ESRD-targeted Areas
Symptoms/problem list74.13 (17.69)77 83 (17.94)69.65 (17.19)80.11 (11.61)*70.31 (13.22)77.74 (18.81)*71.14 (17.96)81.09 (14.84)*0.770.69
Effects of kidney disease63.07 (21.60)66.07 (24.11)59.48 (23.90)65.50 (20.07)63.23 (21.19)68.83 (22.67)69.94 (14.98)73.57 (16.56)0.220.31
Burden of kidney disease31.25 (26.45)28.07 (26.83)28.07 (26.83)17.38 (18.83)20.83 (21.67)30.43 (27.96)21.61 (22.86)24.01 (23.90)0.140.655
Work status19.23 (31.87)23.21 (38.10)1.52 (8.70)15.45 (33.16)*8.06 (22.72)7.89 (21.83)10.00 (23.64)7.89 (21.83)0.030.50
Cognitive: function76.11 (19.11)82.83 (19.31)75.98 (18.59)79.72 (15.95)70.04 (25.10)78.32 (18.75)73.51 (22.93)81.02 (20.83)0.670.67
Quality of social interaction82.36 (20.81)82.99 (18.22)81.05 (15.81)85.41 (17.65)80.32 (18.31)81.52 (19.92)70.70 (23.62)84.60 (19.10)*0.680.76
Sexual function76.39 (28.26)85.16 (21.64)65.63 (31.87)68.75 (30.17)72.50 (25.62)91.25 (16.72)100.00 (0.00)62.50 (36.80)0.500.25
Sleep37.31 (15.94)35.55 (12.55)45.55 (14.09)40.12 (15.70)43.89 (11.89)41.13 (19.49)43.65 (17.07)36.58 (12.68)0.180.21
Social support71.15 (35.76)80.70 (25.74)82.83 (28.71)81.17 (27.86)81.18 (30.04)83.75 (28.11)88.89 (24.88)78.38 (30.65)0.140.86
Dialysis care
Staff encouragement88.94 (23.27)84.72 (27.00)90.53 (16.25)90.45 (17.83)95.56 (8.87)87.50 (24.83)88.89 (22.52)90.97 (17.32)0.440.48
Patient satisfaction71.79 (23.93)59.82 (24.57)*57.58 (23.60)56.36 (21.39)58.33 (21.59)53.51 (26.33)58.77 (17.21)61.84 (24.17)0.040.41
36-item health survey (SF-36)
Physical functioning46.54 (25.56)65.36 (28.31)*31.97 (30.15)52.45 (27.23)*35.78 (31.21)44.63 (32.84)30.00 (28.95)34.34 (23.74)0.14<0.00l
Role-physical35.58 (37.24)37.61 (38.52)16.41 (25.39)27.61 (29.77)*13.67 (20.66)26.64 (36.32)*26.32 (33.49)26.48 (29.26)0.020.27
Pain60.19 (29.15)73.82 (24.03)*49.30 (33.11)67.36 (25.89)*52.06 (30.09)74.39 (22.75)*47.08 (34.39)67.58 (29.58)*0.420.37
General health32.24 (21.48)36.14 (23.00)28.24 (21.41)36.52 (21.08)27.13 (19.05)42.21 (23.69)*35.97 (24.85)38.84 (16.55)0.320.52
Emotional well-being58.00 (25.33)64.91 (23.73)53.48 (20.71)65.82 (24.72)*52.50 (26.61)64.49 (24.84)59.72 (26.62)66.32 (25.54)0.580.98
Role-emotional40.51 (30.40)53.21 (29.83)36.57 (35.36)47.30 (32.93)38.54 (28.62)55.56 (30.06)*41.58 (33.01)42.46 (29.99)0.920.21
Energy/Fatigue49.60 (20.96)51.23 (19.23)44.70 (17.04)49.55 (17.91)42.34 (21.74)55.00 (20.07)*44.72 (20.97)46.76 (20.35)0.600.29
Social function66.83 (34.99)72.59 (32.94)68.75 (35.50)77.50 (29.79)59.77 (38.85)67.50 (33.94)57.57 (37.28)70.07 (32.95)0.540.47
Table 4.  HRQOL results based on the KDQOL-SF instrument for ESRD patients on OL-HDF, according to age (quartiles) and gender.
ESRD patients 1st quartile (< 56 years old) (n=77)ESRD patients 2nd quartile (57–68 years old) (n=86)ESRD patients 3rd quartile (69–75 years old) (n=70)ESRD patients 4th quartile (>75 years old) (n=72)P value (ANOVA analysis)
ESRD–targeted Areas
Symptoms/problem list76.68 (17.83)76.60 (14.63)74.35 (16.80)76.39 (17.02)0.81
Effects of kidney disease65.22 (23.33)63.28 (21.51)66.32 (22.04)71.78 (15.79)0.09
Burden of kidney disease29.01 (26.60)23.22 (22.40)26.19 (25.65)22.86 (23.27)0.35
Work status21.95 (36.09)10.67 (26.67)7.97 (22.07)8.90 (22.58)0.01
Cognitive function80.78 (19.38)78.25 (16.89)74.62 (22.04)77.37 (22.04)0.31
Quality of social interaction82.81 (18.90)83.94 (17.01)80.99 (19.10)77.74 (22.42)0.20
Sexual function83.23 (23.15)68.94 (30.16)85.00 (21.23)75.00 (34.46)0.09
Sleep36.10 (13.62)41.93 (15.30)42.33 (16.56)40.02 (15.29)0.07
Social support77.71 (29.37)82.01 (27.94)82.63 (28.79)83.56 (28.26)0.58
Dialysis care
Staff encouragement86.09 (25.78)90.59 (17.09)91.12 (19.66)89.93 (19.97)0.42
Patient satisfaction63.62 (24.86)57.30 (22.47)55.71 (24.22)60.31 (20.90)0.15
36-item health survey (SF-36)
Physical functioning59.39 (28.70)44.61 (29.77)40.69 (32.21)32.17 (26.39)<0.001
Role-physical36.97 (37.90)23.37 (28.47)20.71 (30.68)26.40 (31.23)0.01
Pain69.55 (26.34)60.92 (29.93)64.36 (28.39)57.33 (33.49)0.06
General health34.94 (22.48)33.45 (21.35)35.41 (22.86)37.43 (20.96)0.72
Emotional well-being62.80 (24.28)61.07 (23.83)59.08 (26.16)63.11 (26.10)0.75
Role-emotional49.14 (30.41)43.18 (34.08)47.89 (30.43)42.02 (31.33)0.42
Energy/Fatigue50.73 (19.66)47.87 (17.60)49.30 (21.63)45.75 (20.54)0.45
Social function70.78 (33.49)74.15 (31.93)64.06 (36.15)63.82 (35.51)0.15
Table 3.  HRQOL results based on the KDQOL-SF instrument for ESRD patients on OL-HDF, according to age (quartiles)
ESRD patients 1st quartile:<56 years oldESRD patients 2nd quartile: 57 – 68 years oldESRD patients 3rd quartile: 69 – 75 years oldESRD patients 4th quartile: >75 years oldP value (ANOVA analysis) womenP value (ANOVA analysis) men
Women (n=25)Men (n=52)Women (n=32)Men (n=54)Women (n=31)Men (n=39)Women (n=35)Men (n=37)
Clinical data, and dialysis adequacy markers
CVC use, n (%)4 (15.4)10 (17.9)12 (36.4)6 (10.9)6 (18.8)5 (12.5)18 (47.4)8 (21.1)0.02#0.52#
FAV use, n (%)22 (84.6)46 (82.1)21 (63.6)49 (89.1)26 (81.3)35 (87.5)20 (52.6)30 (78.9)
Diabetic patients, n (%)6 (23.1)15 (26.8)16 (48.5)18 (52.9)14 (43.8)19 (47.5)10 (26.3)17 (44.7)0.51#0.15*
Hypertensive patients, n (%)6 (23.1)10 (17.9)0 (0)9 (16.4)2 (6.25)8 (20.0)4 (10.5)7 (18.4)0.22#0.97
Previous time on dialysis, months110.08 (254.28)56.74 (69.43)49.42 (65.75)65.20 (11.73)75.50 (202.50)55.75 (72.37)59.32 (122.04)56.95 (44.63)0.550.93
URR, %80.57 (3.59)75.00 (4.71)80.33 (4.59)75.06 (5.85)*78.91 (5.20)74.34 (7.01)*78.12 (7.72)75.74 (7.31)0.250.79
KT/Ve1.71 (0.23)1.47 (0.36)*1.67 (0.24)1.47 (0.34)*1.58 (0.27)1.39 (0.21)*1.61 (0.44)1.49 (0.29)0.430.51
Creatinine, mg/dL8.06 (2.33)9.62 (2.88)*6.46 (2.57)8.68 (2.81)*6.51 (2.68)7.62 (2.76)5.66 (2.38)6.79 (2.32)0.005<0.001
Darbepoeitin, μg/kg/week0.41 (0.44)0.28 (0.42)0.60 (0.97)0.30 (0.39)0.43 (0.39)0.36 (0.46)0.44 (0.40)0.30 (0.39)0.560.79
Hematological data
Hemoglobin, g/dL11.40 (1.72)11.79 (1.32)11.20 (1.44)11.86 (1.42)11.52 (1.16)11.82 (1.23)11.40 (1.42)11.71 (1.33)0.830.96
Hematocrit, %35.11 (5.15)35.97 (4.19)34.99 (4.68)36.31 (4.19)36.04 (3.60)36.39 (3.88)35.60 (4.54)36.15 (4.12)0.770.95
Erythrocytes, ×1012/L3.64 (0.49)3.80 (0.48)3.67 (0.52)3.84 (0.54)3.87 (0.47)3.83 (0.44)3.68 (0.53)3.81 (0.51)0.210.97
MCV, fl96.43 (4.88)95.03 (5.70)97.18 (6.75)94.59 (5.11)93.43 (6.58)95.25 (5.07)97.29 (5.82)95.32 (6.30)0.420.91
MCH, pg31.22 (1.85)31.21 (2.10)29.13 (7.83)30.90 (1.97)28.93 (5.81)30.95 (1.73)31.17 (2.02)30.81 (2.26)0.120.777
MCHC, g/dL32.36 (0.90)32.84 (0.97)31.93 (1.07)32.65 (1.08)31.94 (1.14)32.51 (1.13)32.04 (1.02)32.32 (1.13)0.380.12
RDW, %15.43 (1.80)14.31 (1.31)14.78 (1.78)14.30 (1.07)14.97 (1.60)14.91 (1.46)14.79 (1.40)15.32 (1.99)0.790.79
White blood cells, ×109/L6.39 (1.63)6.93 (2.07)6.04 (1.74)6.40 (1.86)7.07 (2.70)7.26 (2.88)6.94 (3.52)6.37 (1.79)0.370.16
Neutrophil/Lymphocyte ratio2.92 (2.19)2.56 (1.29)3.06 (1.57)2.95 (1.35)2.69 (1.13)3.06 (1.36)2.91 (1.35)2.78 (1.24)0 830.26
Iron status
Iron, mg/dL83.35 (42.19)70.91 (26.33)75.26 (33.94)75.26 (0.89)63.50 (27.72)62.70 (22.18)57.11 (19.53)66.97 (26.42)0.0050.17
Transferrin, mg/dL201.43 (43.50)191.31 (43.09)215.75 (169.97)215.75 (86.81)182.21 (40.02)188.18 (40.66)216.77 (116.62)190.78 (71.01)0.570.44
Transferrin saturation, %29.57 (13.02)28.68 (15.58)32.81 (15.17)32.81 (12.89)26.46 (14.69)24.24 (8.24)22.54 (9.01)26.51 (9.98)0.110.23
Ferritin, ng/mL360.24 (259.14)353.78 (194.25)472.94 (267.15)406.19 (220.43)409.82 (248.99)407.98 (283.99)400.41 (197.62)426.51 (279.13)0.350.47
Inflammatory markers
CRP, mg/dL5.43 (4.78)6.94 (12.89)13.37 (26.27)8.40 (12.56)14.04 (19.84)13.59 (19.91)9.41 (12.42)8.09 (11.91)0.490.27
Nutritional markers
Albumin, g/dL40.44 (12.46)47.06 (13.70)*41.75 (10.69)44.31 (10.04)*39.58 (5.74)43.10 (9.03)37.35 (9.03)41.40 (8.64)*0.240.86
BMI, Kg/m226.18 (5.15)24.17 (3.79)27.77 (5.72)25.66 (4.52)26.88 (4.47)26.27 (3.77)25.38 (4.59)24.27 (3.46)0.230.26
nPCR, g/kg/day1.52 (0.60)1.50 (0.81)1.34 (0.52)1.47 (0.65)1.25 (0.56)1.41 (0.66)1.18 (0.32)1.16 (0.37)0.630.81
Table 2.  Clinical data, hematological and biochemical data, nutritional markers and dialysis adequacy for Total ESRD patients on OLHDF, according to age (quartiles) and gender
ESRD patients 1st quartile (< 56 years old) (n=77)ESRD patients 2nd quartile (57–68 years old) (n=86)ESRD patients 3rd quartile (69–75 years old) (n=70)ESRD patients 4th quartile (>75 years old) (n=72)P value (ANOVA analysis)
Clinical data, and dialysis adequacy markers
CVC use, n (%)14 (17.1)18 (20.5)11 (15.3)26 (34.2)
AVF use, n (%)68 (82.9)70 (79.5)61 (84.7)50 (65.8)0.02#
Diabetic patients, n (%)21 (25.6)35 (39.7)33 (45.8)27 (35.5)0.04#
Hypertensive patients, n (%)16 (19.5)9 (10.2)10 (13.9)11 (14.4)0.40#
Previous time on dialysis, months73.45 (153.70)59.24 (100.67)64.53 (139.66)58.13 (91.28)0.85
URR, %76.75 (5.08)76.99 (5.93)76.34 (6.64)76.93 (7.56)0.92
KT/Ve1.55 (0.34)1.54 (0.32)1.47 (0.25)1.55 (0.38)0.41
Creatinine, mg/dL9.16 (2.81)7.88 (2.92)7.14 (2.76)6.22 (2.41)<0.001
Darbepoeitin, μg/kg/week0.32 (0.43)0.41 (0.69)0.39 (0.44)0.36 (0.40)0.70
Hematological data
Hemoglobin, g/dL11.67 (1.46)11.61 (1.44)11.69 (1.20)11.56 (1.38)0.93
Hematocrit, %35.70 (4.50)35.81 (4.37)36.24 (3.74)35.88 (4.31)0.88
Erythrocytes, x1012 /L3.75 (0.49)3.77 (0.54)3.85 (0.45)3.74 (0.52)0.56
MCV, fl95.47 (5.46)95.61 (5.87)94.46 (5.81)96.31 (6.10)0.28
MCH, pg31.21 (2.01)30.27 (5.05)30.05 (4.17)30.99 (2.14)0.13
MCHC, g/dL32.69 (0.97)32.39 (1.12)32.26 (1.16)32.18 (1.08)0.20
RDW, %14.60 (1.50)14.46 (1.36)14.93 (1.49)14.99 (1.64)0.30
White blood cells, ×109/L6.76 (1.95)6.26 (1.81)7.17 (2.78)6.65 (2.79)0.11
Neutrophil/Lymphocyte ratio2.68 (1.62)2.98 (1.42)2.90 (1.27)2.84 (1.29)0.55
Iron status
Iron, mg/dL74.53 (31.99)74.91 (33.09)63.04 (24.52)61.91 (23.51)0.01
Transferrin, mg/dL194.26 (43.18)209.59 (121.84)185.62 (40.21)204.12 (97.38)0.31
Transferrin saturation, %28.94 (14.81)30.34 (13.80)25.23 (11.53)24.47 (9.64)0.01
Ferritin, ng/mL355.69 (213.85)430.21 (238.55)408.79 (267.16)413.11 (239.42)0.22
Inflammatory markers
CRP, mg/dL6.53 (11.28)10.02 (18.36)13.77 (19.67)8.72 (12.04)0.13
Nutritional markers
Albumin, g/dL45.04 (13.61)43.59 (10.52)41.57 (7.92)39.37 (8.01)0.01
BMI, Kg/m224.80 (4.33)26.46 (5.05)26.54 (4.08)24.82 (4.08)0.01
nPCR, g/kg/day1.51 (0.75)1.43 (0.61)1.34 (0.62)1.17 (0.35)0.01
Table 1.  Clinical data, hematological and biochemical data, nutritional markers and dialysis adequacy for total ESRD patients on OL-HDF, according to age (quartiles)
Figure 1.  Correlations between age and MCHC, iron, transferrin saturation, albumin and nPCR in ESRD patients.
[1] VollmerWMWahlPWBlaggCR1983Survival with dialysis and transplantation in patients with end-stage renal diseaseN Eng J Med30815531558
[2] HeldPJBrunnerFOdakaMGarciaJRPortFKGaylinDS1990Five-year survival for end-stage renal disease patients in the United States, Europe, and Japan, 1982 to 1987Am J Kidney Dis15451457
[3] JagerKJLindholmBGoldsmithDFliserDWiecekASuleymanlarGet al.2011Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the linkKidney Int1suppl 12123
[4] FoleyRNParfreyPSSarnakMJ1998Clinical epidemiology of cardiovascular disease in chronic renal diseaseAm J Kidney Dis32suppl 3S112119
[5] MazairacHAde WitGAGrootemanMPCet al.2012Clinical Performance Targets and Quality of Life in Hemodialysis PatientsBlood Purif337379
[6] MapesDLLopesAASatayathumSet al.2003Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS)Kidney Int64339349
[7] LowrieEGCurtinRBLepainNSchatellD2003Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patientsAm J Kidney Dis4112861292
[8] KnightELOfsthunNTengMLazarusJMCurhanGC2003The association between mental health, physical function, and hemodialysis mortalityKidney Int6318431851
[9] Germin-PetrovićDMesaros-DevcićILesacAMandićMSoldatićMVezmarDPetrićDVujicićBBasić-JukićNRackiS2011Original scientific paper Health-related Quality of Life in the Patients on Maintenance Hemodialysis: The Analysis of Demographic and Clinical Factors Antropol35687693
[10] GibbonsEFitzpatrickR2010A Structured review of patient-reported outcome measures for people with chronic kidney diseaseReport to the Department of Health and NHS Kidney CareUniversity of Oxford
[11] SchmidHSchifflH2012Hemodiafiltration and survival of end-stage renal disease patients: the long journey goes onInt Urol Nephrol4414351440
[12] MaduellFMoresoFPonsMRamosRMora-MaciàJCarrerasJSolerJTorresFCampistolJMMartinez-CastelaoAfor the ESHOL Study Group2013High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis PatientsJ Am Soc Nephrol24487497
[13] MazairacAHde WitGAGrootemanMPet al.2013Effect of hemodiafiltration on quality of life over timeClin J Am Soc Nephrol88289
[14] FrancoMRFernandesNM2013Diálise no paciente idoso: um desafio do século XXI – revisão narrativaJ Bras Nefrol35132141
[15] LaudańskiKNowakZNiemczykS2013Age-related differences in the quality of life in end-stage renal disease in patients enrolled in hemodialysis or continuous peritoneal dialysisMed Sci Monit19378385
[16] RebolloPOrtegaFBaltarJMet al.1998Health-related quality of life HRQOL in end stage renal disease ESRD patients over 65 yearsGeriatr Nephrol Urol88594
[17] HaysRDKallichJDMapesDLCoonsSJCarterWB1994Development of the kidney disease quality of life (KDQOL) instrumentQual Life Res3329338
[18] MapesDLBragg-GreshamJLBommerJet al.2004Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS)Am J Kidney Dis44suppl 25460
[19] UnruhMBenzRGreeneTet al.2004Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO StudyKidney Int66355366
[20] FerreiraPLAnesEJ2010Medição da qualidade de vida de insuficientes renais crónicos: criação da versão portuguesa do KDQOL-SFRev Port Sau Pub283139
[21] Lessan-PezeshkiMRostamiZohreh2009Contributing Factors in Health-Related Quality of Life Assessment of ESRD Patients: A Single Center StudyInt J Nephrol Urol1129136
[22] AneesMHameedFMumtazAIbrahimMSaeed KhanMN2011Dialysis-Related Factors Affecting Quality of Life in Patients on HemodialysisIran J Kidney Dis5914
[23] KnightELOfsthunNTengMLazarusJMCurhanGC2003The association between mental health, physical function and hemodialysis mortalityKidney Int6318431851
[24] SimmonsRGAbressL1990Quality-of-life issues for end-stage renal disease patientsAm J Kidney Dis15201208
[25] Kalantar-ZadehKFouqueDKoppleJD2004Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patientsJ Ren Nutr146471
[26] SchifflH2007Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysisEur J Med Res122633
[27] CuevasXGarcíaFMartín-MaloAFortJLladósFLozanoJPérez-GarcíaR2011Risk Factors Associated with Cardiovascular Morbidity and Mortality in Spanish Incident Hemodialysis Patients: Two-Year Results from the ANSWER StudyBlood Purif332129
[28] YenTHLinJLLin-TanDTHsuCW2010Association between body mass and mortality in maintenance hemodialysis patientsTher Apher Dial14400408
[29] TannerRMBrownTMMuntnerP2012Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney DiseaseCurr Hypertens Rep14152159
[30] Kalantar-ZadehKAbbottKCSalahudeenAKKilpatrickRDHorwichTB2005Survival advantages of obesity in dialysis patientsAm J Clin Nutr81543554
[31] KalenderBOzdemirACDervisogluEOzdemirO2007Quality of life in chronic kidney disease: effects of treatment modality, depression, malnutrition and inflammationInt J Clin Pract61569576
[32] TannerRMBrownTMMuntnerP2012Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney DiseaseCurr Hypertens Rep14152159
[33] Kalantar-ZadehKAbbottKCSalahudeenAKKilpatrickRDHorwichTB2005Survival advantages of obesity in dialysis patientsAm J Clin Nutr81543554
[34] CostaEFernandesJRibeiroSSerenoJGarridoPRocha-PereiraPCoimbraSCatarinaCBeloLBronze-da-RochaEValaHAlvesRReisFSantos-SilvaA2014Aging is Associated with Impaired Renal Function, INF-gamma Induced Inflammation and with Alterations in Iron Regulatory Proteins Gene ExpressionAging Disin press
[35] SeicaASegallLVerzanCet al.2009Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric studyNephrol Dial Transplant24626629
[36] MapesDLBragg-GreshamJLBommerJet al.2004Health-related quality of life in the Dialysis Outcomes and Practice Patterns Study (DOPPS)Am J Kidney Dis44suppl 25460
[37] AstorBCCoreshJPoweNREustaceJAKlagMJ2000Relation between gender and vascular access complications in hemodialysis patientsAm J Kidney Dis3611261134
[38] Stehman-BreenCOSherrardDJGillenDCapsM2000Determinants of type and timing of initial permanent hemodialysis vascular accessKidney Int57639645
[39] AstorBCEustaceJAPoweNRKlagMJSadlerJHFinkNECoreshJ2001Timing of nephrologist referral and arteriovenous access use. The CHOICE StudyAm J Kidney Dis38494501
[40] NgYYWuSCHungYNKoPJ2009Effect of demographic characteristics and timing of vascular access maturation on patency in Chinese incident haemodialysis patientsNephrol Dial Transplant1134473453
[41] van BlijderveenJCStrausSMZietseRStrickerBHSturkenboomMCVerhammeKM2013A population-based study on the prevalence and incidence of chronic kidney disease in the NetherlandsInt Urol Nephrol46583592
[42] ShojiTEmotoMShinoharaKKakiyaRTsujimotoYKishimotoHIshimuraETabataTNishizawaY2001Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal diseaseJ Am Soc Nephrol1221172124
[1] Tingting Sui,Di Liu,Tingjun Liu,Jichao Deng,Mao Chen,Yuanyuan Xu,Yuning Song,Hongsheng Ouyang,Liangxue Lai,Zhanjun Li. LMNA-mutated Rabbits: A Model of Premature Aging Syndrome with Muscular Dystrophy and Dilated Cardiomyopathy[J]. Aging and disease, 2019, 10(1): 102-115.
[2] Yuxiao Liao,Zhao Peng,Liangkai Chen,Yan Zhang,Qian Cheng,Andreas K. Nüssler,Wei Bao,Liegang Liu,Wei Yang. Prospective Views for Whey Protein and/or Resistance Training Against Age-related Sarcopenia[J]. Aging and disease, 2019, 10(1): 157-173.
[3] Dong Liu,Liqun Xu,Xiaoyan Zhang,Changhong Shi,Shubin Qiao,Zhiqiang Ma,Jiansong Yuan. Snapshot: Implications for mTOR in Aging-related Ischemia/Reperfusion Injury[J]. Aging and disease, 2019, 10(1): 116-133.
[4] Wanying Duan, Yuehua Pu, Haiyan Liu, Jing Jing, Yuesong Pan, Xinying Zou, Yilong Wang, Xingquan Zhao, Chunxue Wang, Yongjun Wang, Ka Sing Lawrence Wong, Ling Wei, Liping Liu, . Association between Leukoaraiosis and Symptomatic Intracranial Large Artery Stenoses and Occlusions: the Chinese Intracranial Atherosclerosis (CICAS) Study[J]. Aging and disease, 2018, 9(6): 1074-1083.
[5] Calvin Pak-Wing Cheng, Sheung-Tak Cheng, Cindy Woon-Chi Tam, Wai-Chi Chan, Winnie Chiu-Wing Chu, Linda Chiu-Wa Lam. Relationship between Cortical Thickness and Neuropsychological Performance in Normal Older Adults and Those with Mild Cognitive Impairment[J]. Aging and disease, 2018, 9(6): 1020-1030.
[6] Yu-Wen Huang, Ming-Fu Chiang, Che-Sheng Ho, Pi-Lien Hung, Mei-Hsin Hsu, Tsung-Han Lee, Lichieh Julie Chu, Hsuan Liu, Petrus Tang, Wailap Victor Ng, Dar-Shong Lin. A Transcriptome Study of Progeroid Neurocutaneous Syndrome Reveals POSTN As a New Element in Proline Metabolic Disorder[J]. Aging and disease, 2018, 9(6): 1043-1057.
[7] Manuel Scimeca, Federica Centofanti, Monica Celi, Elena Gasbarra, Giuseppe Novelli, Annalisa Botta, Umberto Tarantino. Vitamin D Receptor in Muscle Atrophy of Elderly Patients: A Key Element of Osteoporosis-Sarcopenia Connection[J]. Aging and disease, 2018, 9(6): 952-964.
[8] Charlene Greenwood, John Clement, Anthony Dicken, Paul Evans, Iain Lyburn, Richard M. Martin, Nick Stone, Peter Zioupos, Keith Rogers. Age-Related Changes in Femoral Head Trabecular Microarchitecture[J]. Aging and disease, 2018, 9(6): 976-987.
[9] Ashok K. Shetty, Maheedhar Kodali, Raghavendra Upadhya, Leelavathi N. Madhu. Emerging Anti-Aging Strategies - Scientific Basis and Efficacy[J]. Aging and disease, 2018, 9(6): 1165-1184.
[10] Ze Teng, Aibo Wang, Peng Wang, Rui Wang, Wei Wang, Hongbin Han. The Effect of Aquaporin-4 Knockout on Interstitial Fluid Flow and the Structure of the Extracellular Space in the Deep Brain[J]. Aging and disease, 2018, 9(5): 808-816.
[11] Stefano Rizza, Marina Cardellini, Alessio Farcomeni, Pasquale Morabito, Daniele Romanello, Giovanni Di Cola, Maria Paola Canale, Massimo Federici. Low Molecular Weight Adiponectin Increases the Mortality Risk in Very Old Patients[J]. Aging and disease, 2018, 9(5): 946-951.
[12] Stefanie Hardt, Lucie Valek, Jinyang Zeng-Brouwers, Annett Wilken-Schmitz, Liliana Schaefer, Irmgard Tegeder. Progranulin Deficient Mice Develop Nephrogenic Diabetes Insipidus[J]. Aging and disease, 2018, 9(5): 817-830.
[13] Yong-Fei Zhao, Qiong Zhang, Jian-Feng Zhang, Zhi-Yin Lou, Hen-Bing Zu, Zi-Gao Wang, Wei-Cheng Zeng, Kai Yao, Bao-Guo Xiao. The Synergy of Aging and LPS Exposure in a Mouse Model of Parkinson’s Disease[J]. Aging and disease, 2018, 9(5): 785-797.
[14] Diano F. Marrone, Elham Satvat, Anuj Patel. Age-related Deficits in Recognition Memory are Protocol-Dependent[J]. Aging and disease, 2018, 9(5): 798-807.
[15] Maxime Fournet, Frederic Bonte, Alexis Desmouliere. Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging[J]. Aging and disease, 2018, 9(5): 880-900.
Viewed
Full text


Abstract

Cited

  Shared   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd